Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus

Lead Sponsor:

Handok Inc.

Conditions:

Type 2 Diabetes Mellitus

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The study design of this trial is double blind, parallel-group, randomized, placebo controlled study

Detailed Description

* Although many different oral antidiabetic agents are currently available, approximately 50% of treated Type 2 diabetic subjects do not reach currently accepted goals for HbA1c(Oral communication, Am...

Eligibility Criteria

Inclusion

  • The subject is aged ≥18 years at signature of the informed consent form
  • The subject has a documented diagnosis of Type 2 diabetes
  • The subject's HbA1c is 7.0%≤HbA1c\<10.0% at screening visit and run-in visit
  • The subject's BMI is 20.0≤BMI≤40.0kg/m2
  • The subject's fasting plasma glucose is \<15 mmol/L (270 mg/dL)at screening visit and run-in visit
  • The subject conducts a proper diet and exercise therapy for diabetes and its contents have not been changed for at least 8 week(56 days) at run-in visit(this does not apply to a subject with complications as as result of that exercise therapy is impossible)
  • The subject has not used other diabetic medicine for at least 8 week(56 days) at run-in visit
  • The subject is capable of giving informed consent, complying with the restrictions and requirements of the protocol

Exclusion

  • The subject has a history of Type 1 diabetes or a secondary form of diabetes(Diabetes caused by the pancreatic diseases, such as chronic pancreatitis, pancreatic cancer, hemochromatosis or the overproduction of hormones antagonistic to insulin, Cushing's syndrome, Basedow's disease, pheochromocytoma, drug, insulin receptor abnormalities)
  • The subject has a history of MP-513 treatment
  • The subject has a history of habitual and excessive alcohol abuse or drug abuse, or concerns
  • The subject has a medical history of unstable angina, or heart failure(New York Heart Association class Ⅲ-IV) or any clinically significant ECG abnormalities such as ventricular tachycardia or a medical history of ventricular tachycardia
  • The subject has participated in any other clinical study involving administration of an unlicensed medicinal product within 12 weeks prior to the screening visit or is participating any other clinical study
  • The subject has received insulin within 12 months prior to the screening visit, with the exception of insulin therapy during hospitalization, insulin therapy for medical conditions not requiring hospitalization (\<2 weeks duration) or use in gestational diabetes
  • Female subjects whose pregnancy test is positive or who are pregnant, lactating, or are planning to become pregnant during the study
  • The subject has serum creatinine \>1.5 mg/dL(male) or \>1.4 mg/dL(female)
  • The subject has aspartate-amino-transferase (AST) and alanine-amino-transferase (ALT) \>2.5 times the upper limit of normal (ULN)
  • The subject has diastolic blood pressure \>100 mmHg and/or systolic blood pressure \>180 mmHg
  • The presence of any other condition that leads the investigator to conclude that the patient is inappropriate for inclusion in the clinical study

Key Trial Info

Start Date :

November 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2014

Estimated Enrollment :

142 Patients enrolled

Trial Details

Trial ID

NCT01798238

Start Date

November 1 2012

End Date

May 1 2014

Last Update

August 5 2014

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Handok INC

Seoul, Gangnam-Gu, South Korea

2

Handok Pharmaceuticals CO. LTD

Seoul, South Korea